Pharmaceuticals
Commercializing and developing pharmaceuticals addressing large unmet needs
Improving the lives of people suffering from mental illness and substance use disorders
What we do
Digital Therapeutics
Product portfolio of scientifically proven digital therapies
Mental illness & substance use disorders
Focusing on areas of great human suffering with wider societal implications
MODIA™ - our digital therapy for opioid dependence
- to be used along with pharmaceuticals
- 6 months treatment
- grounded in cognitive behavioral therapy techniques
- available 24/7
- ongoing clinical trial incl. up to 400 patients
Key News
NOVEMBER 26, 2021
Orexo provides information about its new proprietary drug delivery platform – amorphOX™
NOVEMBER 16, 2021
Positive results from pivotal trial for OX124
NOVEMBER 3, 2021
Q3 Interim Report - Steady progression on our journey to build a broader and stronger Orexo
Orexo Social
@OrexoABpubl
29 November 2021
Today #orexo looks forward to present at @aktiespararna Stora Aktiedagen. At 2 pm Nikolaj Sørensen CEO will give a… https://t.co/k9oRXZLJUe
@OrexoABpubl
26 November 2021
amorphOX™, is an inventive powder-based technology, that is very rapidly dissolving, stable & works with different… https://t.co/uuH4sJEwfT
@OrexoABpubl
26 November 2021
Today we are proud to inform about the amorphOX™ platform, our new proprietary drug delivery technology, which will… https://t.co/V0s2CTLGcQ
Our history
Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.
News Flow
Press Releases & News
Orexo provides information about its new proprietary drug delivery platform – amorphOX™
Orexo´s Nomination Committee for the Annual General Meeting 2022
Invitation to presentation of Orexo´s Q3 Interim Report, on November 3 at 1 pm CET
MODIA™ paper published in the Journal of Medical Internet Research Mental Health
Financial Snapshot
Group net revenues
580 MSEK
LTM1
Group EBITDA
-112 MSEK
LTM1
US Pharma segment EBIT
301 MSEK
LTM1
Cash position
588 MSEK
Q3 2021
1 Last Twelve Months, Q420-Q321, for more information about financial development Link